About Amedisys Home Health and Hospice Care (NASDAQ:AMED)
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031
Debt
Debt-to-Equity Ratio0.15%
Current Ratio1.45%
Quick Ratio1.45%
Price-To-Earnings
Trailing P/E Ratio30.24
Forward P/E Ratio22.28
P/E Growth1.27
Sales & Book Value
Annual Sales$1.53 billion
Price / Sales1.48
Cash Flow$2.7631 per share
Price / Cash24.19
Book Value$15.22 per share
Price / Book4.39
Profitability
EPS (Most Recent Fiscal Year)$2.21
Net Income$30.30 million
Net Margins1.98%
Return on Equity15.14%
Return on Assets9.56%
Miscellaneous
Employees17,900
Outstanding Shares33,990,000
Amedisys Home Health and Hospice Care (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys Home Health and Hospice Care's stock symbol?
Amedisys Home Health and Hospice Care trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys Home Health and Hospice Care's earnings last quarter?
Amedisys Home Health and Hospice Care (NASDAQ:AMED) issued its earnings results on Tuesday, February, 27th. The health services provider reported $0.56 EPS for the quarter, missing the Zacks' consensus estimate of $0.58 by $0.02. The health services provider had revenue of $404.24 million for the quarter, compared to analysts' expectations of $394.96 million. Amedisys Home Health and Hospice Care had a return on equity of 15.14% and a net margin of 1.98%. During the same period last year, the business posted $0.44 earnings per share. View Amedisys Home Health and Hospice Care's Earnings History.
When is Amedisys Home Health and Hospice Care's next earnings date?
What guidance has Amedisys Home Health and Hospice Care issued on next quarter's earnings?
Amedisys Home Health and Hospice Care issued an update on its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $2.97-3.08 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.66. The company issued revenue guidance of $1.60-1.64 billion, compared to the consensus revenue estimate of $1.63 billion.
What price target have analysts set for AMED?
11 Wall Street analysts have issued 12 month target prices for Amedisys Home Health and Hospice Care's shares. Their predictions range from $54.00 to $70.00. On average, they expect Amedisys Home Health and Hospice Care's share price to reach $62.90 in the next twelve months. View Analyst Ratings for Amedisys Home Health and Hospice Care.
Who are some of Amedisys Home Health and Hospice Care's key competitors?
Some companies that are related to Amedisys Home Health and Hospice Care include Envision Healthcare (EVHC), Sartorius (SARTF), Indivior (INVVY), Integra lifesciences (IART), Premier (PINC), Hutchison China MediTech (HCM), Medidata Solutions (MDSO), LivaNova (LIVN), Orion (ORINY), Penumbra (PEN), Ablynx (ABLYF), Ablynx (ABLX), Haemonetics (HAE), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), Healthequity (HQY), Elekta (EKTAY) and Syneos Health (SYNH).
Who are Amedisys Home Health and Hospice Care's key executives?
Amedisys Home Health and Hospice Care's management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Chief Exec. Officer, Pres and Director (Age 57)
- Mr. Scott G. Ginn, CFO & Principal Accounting Officer (Age 49)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 51)
- Mr. Pete Hartley, Chief Technology Officer and Sr. VP of Bus. Operations Systems
- Mr. Michael P. North, Chief Information Officer (Age 53)
Has Amedisys Home Health and Hospice Care been receiving favorable news coverage?
News articles about AMED stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amedisys Home Health and Hospice Care earned a news impact score of 0.05 on Accern's scale. They also gave press coverage about the health services provider an impact score of 46.85 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Amedisys Home Health and Hospice Care's major shareholders?
Amedisys Home Health and Hospice Care's stock is owned by a number of of retail and institutional investors. Top institutional investors include
FMR LLC
(2.94%). Company insiders that own Amedisys Home Health and Hospice Care stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Institutional Ownership Trends for Amedisys Home Health and Hospice Care.
How do I buy shares of Amedisys Home Health and Hospice Care?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedisys Home Health and Hospice Care's stock price today?
One share of AMED stock can currently be purchased for approximately $66.84.
How big of a company is Amedisys Home Health and Hospice Care?
Amedisys Home Health and Hospice Care has a market capitalization of $2.27 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys Home Health and Hospice Care employs 17,900 workers across the globe.
How can I contact Amedisys Home Health and Hospice Care?
Amedisys Home Health and Hospice Care's mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys Home Health and Hospice Care (AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys Home Health and Hospice Care and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
Amedisys Home Health and Hospice Care (NASDAQ:AMED) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Amedisys Home Health and Hospice Care in the last 12 months. Their average twelve-month price target is $62.90, suggesting that the stock has a possible downside of 5.89%. The high price target for AMED is $70.00 and the low price target for AMED is $54.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.64 | 2.64 | 2.55 | 2.40 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $62.90 | $62.90 | $61.00 | $56.20 |
| Price Target Upside: | 5.89% downside | 0.27% upside | 15.79% upside | 11.80% upside |
Amedisys Home Health and Hospice Care (NASDAQ:AMED) Consensus Price Target History
Amedisys Home Health and Hospice Care (NASDAQ:AMED) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Amedisys Home Health and Hospice Care (NASDAQ:AMED) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Amedisys Home Health and Hospice Care (NASDAQ AMED) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 94.99%
Amedisys Home Health and Hospice Care (NASDAQ AMED) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/8/2017 | David B Pearce | Insider | Sell | 1,000 | $50.00 | $50,000.00 | 10,488 |  |
| 8/3/2017 | Bruce D Perkins | Director | Buy | 2,000 | $46.60 | $93,200.00 | 15,825 | |
| 5/25/2017 | Bruce D Perkins | Director | Buy | 500 | $59.69 | $29,845.00 | 13,331 | |
| 5/12/2017 | Jake L Netterville | Director | Sell | 10,000 | $60.00 | $600,000.00 | 77,499 | |
| 5/10/2017 | Lawrence R Pernosky | Insider | Sell | 11,500 | $58.97 | $678,155.00 | 30,093 | |
| 5/9/2017 | Lawrence R Pernosky | Insider | Sell | 11,500 | $58.78 | $675,970.00 | 30,093 | |
| 5/8/2017 | Scott G Ginn | Insider | Sell | 23,828 | $58.62 | $1,396,797.36 | 13,018 | |
| 5/13/2016 | Bruce D Perkins | Director | Buy | 1,000 | $50.21 | $50,210.00 | 10,354 | |
| 5/11/2016 | Scott G Ginn | Insider | Sell | 6,000 | $51.62 | $309,720.00 | 48,009 | |
| 11/2/2015 | North Tide Capital, Llc | Major Shareholder | Sell | 277,720 | $39.79 | $11,050,478.80 | | |
| 10/28/2015 | North Tide Capital, Llc | Major Shareholder | Sell | 191,400 | $39.86 | $7,629,204.00 | | |
| 10/26/2015 | North Tide Capital, Llc | Major Shareholder | Sell | 56,400 | $39.32 | $2,217,648.00 | | |
| 8/18/2015 | Donald A Washburn | Director | Sell | 20,000 | $45.51 | $910,200.00 | | |
| 3/13/2015 | Jeffrey D Jeter | Insider | Sell | 11,264 | $27.02 | $304,353.28 | | |
| 3/13/2015 | Peter Ricchiuti | Director | Sell | 2,003 | $27.25 | $54,581.75 | | |
| 8/5/2014 | Jeffrey D Jeter | Insider | Sell | 2,500 | $21.80 | $54,500.00 | | |
| 5/8/2014 | North Tide Capital, Llc | major shareholder | Buy | 500,000 | $13.90 | $6,950,000.00 | | |
| 5/1/2014 | North Tide Capital, Llc | major shareholder | Buy | 150,000 | $13.54 | $2,031,000.00 | | |
| 11/21/2013 | Kkr Asset Management Llc | major shareholder | Buy | 425,515 | $14.48 | $6,161,457.20 | | |
| 11/15/2013 | David Bucey | General Counsel | Sell | 8,290 | $13.95 | $115,645.50 | 13,057 | |
| 11/14/2013 | Kkr Asset Management Llc | major shareholder | Buy | 946,500 | $13.89 | $13,146,885.00 | | |
| 10/30/2013 | Kkr Asset Management Llc | Major Shareholder | Buy | 29,615 | $15.94 | $472,063.10 | | |
| 10/22/2013 | Kkr Asset Management Llc | Major Shareholder | Buy | 186,013 | $17.55 | $3,264,528.15 | | |
| 10/18/2013 | Kkr Asset Management Llc | Major Shareholder | Buy | 12,652 | $17.95 | $227,103.40 | | |
| 7/3/2013 | Linda J Hall | Director | Sell | 1,721 | $10.65 | $18,328.65 | | |
(Data available from 1/1/2013 forward)
Amedisys Home Health and Hospice Care (NASDAQ AMED) News Headlines
| Source: |
|
Amedisys Home Health and Hospice Care (NASDAQ:AMED) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Amedisys Home Health and Hospice Care (NASDAQ:AMED) Income Statement, Balance Sheet and Cash Flow Statement
Amedisys Home Health and Hospice Care (NASDAQ AMED) Stock Chart for Monday, April, 23, 2018
Loading chart…
